Loading...
Loading...
EDSA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 45.0K |
| Gross Profit | -45.0K |
| Operating Expense | 1,812.4K |
| Operating I/L | -1,857.4K |
| Other Income/Expense | 179.0K |
| Interest Income | 61.0K |
| Pretax | -1,678.5K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -1,678.5K |
Edesa Biotech, Inc. is a biopharmaceutical company specializing in the acquisition, development, and commercialization of clinical-stage drugs for inflammatory and immune-related diseases with unmet medical needs. The company's lead product candidates include EB05, a monoclonal antibody in Phase 3 clinical study for treating acute respiratory distress syndrome in covid-19 patients, and EB01, a topical treatment in Phase 2B clinical study for chronic allergic contact dermatitis. Additionally, Edesa Biotech has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10, positioning the company at the forefront of innovative treatments for these conditions.
